Site Navigation
Categories:
Non-nucleoside reverse transcriptase inhibitors
Alkynes
Bristol-Myers Squibb

Summary Of: Efavirenz

on Antiretroviral Guidelines currently recommends the use of efavirenz in combination with... Efavirenz is also used in combination with other... Efavirenz was combined with the popular... Efavirenz was approved by the... Efavirenz is used to treat... efavirenz has been used as first line treatment in preference to the... trial showed that the potency of efavirenz is maintained at all... Efavirenz falls in the non... Efavirenz is not effective against HIV... viral strains which are resistant to efavirenz are usually also resistant to the other NNRTIs... The most common mutation observed after efavirenz treatment is K103N... The usual adult dose of efavirenz is 600mg per day... Efavirenz is metabolized in the liver... This means efavirenz may interact with other drugs metabolized in the liver... Efavirenz lowers blood levels of most... Use of efavirenz can produce a... efavirenz is quite expensive... Efavirenz is chemically described as... Efavirenz is a white to slightly pink crystalline powder with a molecular mass of 315...

Encyclodia Page On: Efavirenz

These Are Links To Other Documents
| | IUPAC | CAS number | ATC code | J05 | PubChem | DrugBank | Formula | C | H | Cl | F | N | O | Mol. mass | g | mol | SMILES | Bioavailability | Protein binding | Metabolism | Hepatic | CYP3A4 | CYP2B6 | Half life | Excretion | Renal | Pregnancy cat. | U.S. | Legal status | UK | Routes | non-nucleoside reverse transcriptase inhibitor | HAART | HIV | United States Department of Health and Human Services | lamivudine | zidovudine | Combivir | tenofovir | emtricitabine | Truvada | antiretroviral | postexposure prophylaxis | mg | neurological | psychiatric | HIV | medication | Truvada | tenofovir | emtricitabine | reverse transcriptase inhibitors | FDA | Atripla | HAART | Food and Drug Administration | September 21 | 1998 | HIV | HIV viral load | lopinavir | protease inhibitors | HIV viral loads | reverse transcriptase | nevirapine | delavirdine | rifampicin | tuberculosis | 3A4 | cytochrome P450 | protease inhibitors | amprenavir | atazanavir | indinavir | saquinavir | St John's wort | garlic | insomnia | confusion | memory loss | depression | Rash | nausea | dizziness | headache | birth defects | false positive | marijuana | hallucinogenic | dissociative | HIV | insoluble | doi | v | d | Antivirals | HIV | HAART | J05 | Nucleoside & Nucleotide
Reverse Transcriptase
Inhibitors (NRTI) | Abacavir (ABC) | Emtricitabine (FTC) | KP-1461 | Lamivudine (3TC) | Tenofovir | Didanosine (ddI) | Zidovudine (AZT) | Apricitabine | Stampidine | Elvucitabine | Racivir | Amdoxovir | Stavudine (d4T) | Zalcitabine (ddC) | Non-Nucleoside
Reverse Transcriptase
Inhibitors (NNRTI) | Nevirapine | Etravirine | Rilpivirine | Loviride | Delavirdine | Protease Inhibitors (PI) | Atazanavir | Brecanavir | Fosamprenavir | Lopinavir | Darunavir | Nelfinavir | Ritonavir | Saquinavir | Tipranavir | Amprenavir | Indinavir | Entry/fusion inhibitors | Aplaviroc | Enfuvirtide | Maraviroc | Vicriviroc | PRO 140 | Ibalizumab | Integrase inhibitors | Raltegravir | Elvitegravir | Maturation inhibitors | Bevirimat | Vivecon | Combined formulations | Combivir | Atripla | Trizivir | Truvada | Kaletra | Epzicom | Abzyme | Calanolide A | Ceragenin | Cyanovirin-N | Diarylpyrimidines | Epigallocatechin gallate (EGCG) | Foscarnet | Globoidnan A | Griffithsin | Hydroxyurea | Miltefosine | Portmanteau inhibitors | Seliciclib | Synergistic enhancers | Tre recombinase | Zinc finger protein transcription factor | DHHS | first-line agent | clinical trials | FDA | Development | Categories | Non-nucleoside reverse transcriptase inhibitors | Alkynes | Bristol-Myers Squibb |
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Efavirenz".